Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.56 |
| ▸ | CA1 | P00915 | 6/20 | 0.56 |
| ▸ | CA2 | P00918 | 6/20 | 0.56 |
| ▸ | CA7 | P43166 | 6/20 | 0.56 |
| ▸ | CA9 | Q16790 | 6/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1205732 | 0.86 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL129924 | 0.86 | TSHR (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6196633 | 0.82 | TSHR (0.59) | TSHRALDH1A1HSD17B10ESR1NPC1 | |
| SCHEMBL4738309 | 0.81 | CYP4F2 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19212264 | 0.81 | TSHR (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27999935 | 0.81 | TSHR (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29258466 | 0.81 | TSHR (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27617822 | 0.80 | CA1 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1978589 | 0.80 | LMNA (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1809516 | 0.80 | TSHR (0.49) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0705260-B1 | CONDENSED 4-AMINOPYRIDINES WITH ANTIRHEUMATIC ACTIVITY | KNOLL AG (DE) | 1999-03-03 | — | — | EP | claimed |
| US-5780482-A | TREATING RHEUMATIC DISEASES | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-07-14 | — | — | US | claimed |
| EP-0705260-A1 | CONDENSED 4-AMINOPYRIDINES WITH ANTIRHEUMATIC ACTIVITY | KNOLL AKTIENGESELLSCHAFT (DE) | 1996-04-10 | — | — | EP | claimed |
| WO-1995000511-A1 | CONDENSED 4-AMINOPYRIDINES WITH ANTIRHEUMATIC ACTIVITY | KNOLL AG (DE) | 1995-01-05 | — | — | WO | claimed |
| US-20190345190-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-17 | — | — | US | disclosed |
| US-9957225-B2 | Treatment of friedreich's ataxia using histone deacetylase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170088576-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9579332-B2 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9457035-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| WO-1996026933-A9 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | — | 1996-11-28 | — | — | WO | disclosed |
| WO-1996033200-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | ÚSTAV ORGANICKÉ CHEMIE A BIOCHEMIE AKADEMIE VED C^¿ESKÉ REPUBLIKY (CZ) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996026933-A1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES, INC. (US) | 1996-09-06 | — | — | WO | disclosed |
| WO-1996023801-A2 | NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME | GILEAD SCIENCES, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0705260-A1 | CONDENSED 4-AMINOPYRIDINES WITH ANTIRHEUMATIC ACTIVITY | KNOLL AKTIENGESELLSCHAFT (DE) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| WO-1995000511-A1 | CONDENSED 4-AMINOPYRIDINES WITH ANTIRHEUMATIC ACTIVITY | KNOLL AG (DE) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088576-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, ITPA | CA12 3641/4885CA1 3835/4885CA2 2232/4885 |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | CA12 4458/4885CA1 4095/4885CA2 3233/4885 |
| US-20190345190-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | CA12 4458/4885CA1 4095/4885CA2 3233/4885 |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | PIK3CA, TYMP, ITPA | CA12 4458/4885CA1 4095/4885CA2 3233/4885 |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | CA12 4458/4885CA1 4095/4885CA2 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.